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Introduction
We live in an era of specialization. Yet biotechnology, used
here in the restricted sense of recombinant DNA technology,
is presenting society with profound issues that will require
diverse interdisciplinary talent and thinking for solution. In
order to understand the implications of the use of a genetically engineered organism ( GEO) in an agricultural or environmental application, for example, it may be necessary to
understand subtle implications of 1) its molecular biology, 2)
its organismal and population biology, 3) its potential for
microevolutionary adaptive change, 4) the local ecology, 5)
the local socioeconomics, and 6) the national and international context of economics and technological development.
Someone who is trained to make genetic alterations to
produce one desired goal; e.g. , a bacteria that produces a new
useful chemical, is not necessarily educated to anticipate, to
recognize, or to study the complex implications of such
genetic changes for the complete habits of the living organism. Moreover, as in medicine, much art and hands-on experience goes into even an imperfect understanding of how a
change in one part of a living organism may alter its functions
and habits. Good theories do not yet exist to explain just how
changing a few genes may change the complete adult organism. Science is several Nobel Prizes away from that.
It is molecular biologists and genetic engineers who hold
the powerful tools for creating new forms of life. Theirs are
fast-moving, competitive, and demanding fields. They do not
usually have the time, incentive, or institutional support to
equip themselves to deal more than superficially with the
complex biological, economic, institutional, and ethical
issues that their technology generates. They are typically biochemists or laboratory microbiologists who are learning to
extend their techniques to the manipulation of new tissues
such as those of plants, animals, and "wild-type," nonlaboratory, microorganisms. Where shall society get the counsel that
it deserves? It is widely believed that biotechnology will
impact upon human affairs as profoundly as the Industrial
Revolution. Yet, scientists of various types are being thrust into
positions of responsibility and power for which their backgrounds do not prepare them.
The development of biotechnology is most likely to be
effective, efficient, and fair if society develops a competent
infrastructure to deal with it. This would include a diverse
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body of appropriately educated scientists, scholars, policymakers, and ordinary citizens who can make good judgments
about what are, in many cases, unprecedented issues. It would
also include networking modes both outside and within
government and industry for information and talent exchange,
and for participation in decisionmaking.
Societies have a way of muddling along and many people
expect and aspire to no more. They need read no further. This
communication is not for them. It may not be the end of the
world if biotechnology is not wisely handled. But I write with
the basic presumption that the reader is interested in exploring some alternatives to leaving this issue to the generosity of
fate , and to the skills of poorly prepared professionals. I
elaborate now on the issue of need. Some more specific
suggestions for the types of talents needed, especially in biology, are discussed in Regal (1) .

Historical Difficulties for Public Discussion
There is much uncertainty and little consensus about the
seriousness of any one of the following issues. The state of
uncertainty has led to a statistical spread of opinion on each
issue-some people are surely underconcerned while others
are overconcerned As is usual in human affairs, the extreme
positions often react strongly and with outrage to each other's
excesses and are also the most visible in public debate. The
middle gets neglected or is misrepresented, and the standards
for public discussion remain low. This polarization can discourage conscientious and thoughtful citizens from participation in matters that will affect them and their children.
It cannot be emphasized too strongly that the polarization
today in large part is a legacy from "the great debate" of the
1970s, which centered on the possibility of a laboratory acci dent that might produce an "Andromeda Strain" (2, 3, 4).
Analysis and experience have shown that the emotional con cerns were highly excessive. I.aboratory strains are unlikely to
survive and spread in nature. Any new pathogens can be
handled relatively safely with established methods.
New questions have been raised, though, concerning organisms that are engineered to be competitive in nature. It is
diffiCult, for example, to predict the effects of the introduction
into nature of vigorous bacterial "goats" or weedy plants
engineered to "eat up, " or metabolize, a range of chemicals
including environmental pollutants. Even costly misjudgJournal of the Minnesota Academy o f Science

ments here would probably not have the dramatic severity of
an "Andromeda Strain" (5, 6, 7). Yet some influential scientists
greatly fear that the exploration of relatively modest environmental or health concerns will reopen the lid ofPandora's box
to the reputed crazy, hysterical fears of"killer tomatoes," and
the "corn that invaded the Bronx."
Some in biotechnology see any efforts to put scientific,
social, institutional, or economic concerns into perspective
merely as irresponsible lid-raising. They live in dread of
renewed "public hysteria." They would seem to have a point
since subtle thought is not commonly encountered. Yet, the
American public has, in fact, been generously supportive of
biotechnology, despite "the great debate" and it does not
seem realistic to sweep legitimate public concerns under the
rug putatively to save the industry.
Indeed, the public has come very much to want genetic
engineering. When local governments and the courts have
delayed projects, and Congress has shown concern, it has
often been because of suspicions raised by industrial secrecy
and by the impressions of insufficient discussion among
experts of potential consequences. Concern exists that the
American institutions of due process, thorough discussion,
and of checks and balances may be circumvented. Actually,
one hears almost no serious concern for "sludge monsters"
anymore. Without understanding their history, it would be
hard to understand why genetic engineers often equate all
public concerns with ignorance and hysteria.
The situation that has resulted is most unfortunate, but its
very irrationality and superficiality underscores the profound
extent of the unknowns and the critical need for public vehicles to promote responsible discussion of such issues. In this
sense, and with this warning, it is useful to list issues of
potential concern. This list should in no way be taken to slight
the immense potential benefits ofbiotechnology, which have
been widely discussed. On the contrary, the aim is to devise
ways to realize the benefits of the new technology.

Pragmatic Concerns
In a pluralistic society, policy debate is more likely to focus
on pragmatic concerns of national security, the economy,
health, the environment, justice, and institutional vitality than
of issues with a distinct sectarian basis. The following pragmatic concerns have been raised in a number of books and
articles by knowledgable people.
Security
Biological warfare arms-race seems to have been renewed
with the Soviet Union. The potential dangers are disputed
by the experts (8)."

Terrorism. Cheap and psychologically powerful threats
could become available, some experts warn.
Economic
Loss in the United States' competitive position if any obstacles to development are created. This is a major belief in
industry and Washington.
Misdirection of public funds to support private interests
against public interests. (For example, increased milk production might help some scientists and dairy people to
profit, but hurt the industry and the taxpayers who subsidize surpluses; may hurt the national and international
economies.)
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Health
Misdesign leading to diseases or to harmful side effects.
(For example, it is not widely appreciated that some vectors could theoretically have carcinogenic effects. There
may be sufficient safeguards in the system already to
explore such issues in timely fashion.)
Neglect of nonprofitable illnesses. (e.g., in the early 1980s a
leading company would not develop an antimalarial vaccine for the World Health Organization unless assured a
monopoly on the profits (9), despite public funding of
research.)
Environmental
Mismanagement of nature with powerful new technology.
Ability to alter nature expected to advance faster than ability
to understand the implications of this.
Misdesign leading to rogue species. Genetic engineering is
not true engineering where the properties of materials and
designs are well understood and results are highly predictable. Airplanes and bridges are not subject to pleiotropic
effects, genetic rearrangements, adaptive plasticity.
justice
Commercial takeover of publicly developed technology.
Federal, state, and foundation funds have developed biotechnology. Is it fair for private companies to "run off' with
all the profits? If not, who should get what? Universities are
trying to obtain profits, but currently they are spending
more than many believe they can expect to gain. How
much do they deserve?
Should a particular researcher's or company's project be
delayed because of concerns over broader social or economic issues, or because of hypothetical concerns over
health or safety?
Private, corporate experimentation with the environment,
with "the commons." Who should be allowed to experiment with nature in ways that may not be able to be
undone? How freely? Who does nature belong to?
Passing any mistakes on to other countries, future
generations.
Should the public pay the costs of any health, environmental mistakes, or of any institutional dislocations by industry?
Who will make important decisions with possibly profound economic, social, moral, and environmental consequences? Who will assume these powers? The marketplace? Bureaucracy? Politicians? Courts? Other?
Institutional
Does ease of entrepreneurial activity create new qualitative
or quantitative dimensions of conflict of interest for academic scientists? Concentration of political control in
' biology?
Loss of the university, National Academy, etc., as societal
resources for objective analysis and forums for scholarly
debate. Panem (10) and Murray (9) discuss additional
aspects of this complex general issue.
Development of a "University-Industrial-Federal Complex."
Concentration of power over agricultural/rural America
(and internationally) in the hands of an agribusinessuniversity-USDA complex.
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Industry may need so much political and economic support that the fundamental relationships of government to
industry may transform radically. (For example, government subsidy of industry through technology development
and economic leverage on universities, or patenting of life,
which has long been regarded as property of "the commons," or relaxed regulations.)

Theological/Phllosophical Concerns
Most religions and philosophies do not seem to have identified concerns about the creation of new life forms. However,
some in the Greco- Christian tradition strongly question violating the natural order of things. The natural order is seen as
reflecting the intentions of God, or the will of God. Changing
that, particularly for selfish reasons, or with overt or covert
motives of self-love, or pride, is seen as defiance of the will of
God.
Genetic manipulation of the unborn, of germ lines, is
widely agreed to be morally unacceptable. This is not a sectarian issue in the United States. It seems quite unlikely that
Western Society will be creating reproducing lines of genetically engineered super-soldiers, airline pilots, or basketball
players.

Socioeconomic Obstacles to the Development of
an Infrastructure
·
Industry
The biotechnology industry has raised an enormous amount
of venture capital. It is based on enormous public investments
in basic research, but it has not yet produced significant
income for this $15 to 20 billion investment. Individuals are
pr~oc~upied with presenting a positive, fresh, exciting image
of mdividual, corporate, and industry progress and with sustaining the interest of investors. They are busy trying to
develop products. These are matters of survival.
The industry has had its own problems. It has been common to find scientists who know little about business and
businesspeople who know little about science trying to compete in complex ventures. Organisms have proved to be more
difficult to work with than the molecular biologists anticipated (recall the unearned Nobel Prizes mentioned above)
and progress has been slower than projected on many projects
(11).
There is hardly time to think about a broad societal infrastructure. There are no obvious personal incentives for this.
Indeed, industry may see talk of a need for an infrastructure as
raising concerns to venture capitalists that could threaten a
company's image and survival. They may tend to label such
talk as "negativism" or "doom and gloom." It is in the economic interests of the industry as a whole to minimize potential risks and problems. But, it may be difficult for individuals
to advance up career ladders, and be seen as "team players,"
unless they voice personal concerns discreetly and balance
broad concerns with optimistic enthusiasm for industry prospects. That would not be the easiest path to follow for many
ambitious people. The issue is made particularly difficult
since the public concerns are often of a broad and general
nature, and the seriousness of their impact is necessarily
uncertain in these early days.
In the most cynical scenario, the dynamics of self-interest
would threaten to lead toward a group psychology of stonewalling, or even denial, in the biotechnology industry that
could be parallel to that in, for example, the tobacco industry.
Here, the industry adopted a self-serving group perception

based on the early questionable nature of the arguments
linking smoking and cancer. By the time the data had
improved, the industry had become "philosophical" and
closed-minded. Even faced with damning statistical data, one
could always argue, for example, that the sale of a single
package of cigarettes carries a vanishingly small probability of
risk. So if any issue exists, it can only be in abuse of the
product.
Scientists in the biotechnology industry have assured me
that widespread concern exists within the industry itself for
the issues raised here and that biotechnology is still far from
being absorbed in a dialogue of denial. Yet even these concerned scientists generally agree that some socioeconomic
factors in industry work against the development of an infrastructure to deal with concerns.
Appealing to the long-term interests of the industry is more
likely to be effective with large companies that take longrange corporate outlooks. But even here uneasiness exists
since there is uncertainty about prospects for profit, and since
biotechnology programs must justify themselves in the shortrun to major shareholders against other company options.
Smaller companies are generally less able to give attention
to societal issues since survival is more nearly a daily concern.
Many small companies foresee eventually selling out to larger
companies and may not take a long-range outlook in any
event.
The University
Academic molecular biologists and genetic engineers are
not necessarily free of socioeconomic influences. It can be
relatively inexpensive to apply for a patent and form a small
biotechnology company. Many have done this, even running
companies on university property. The line between federally
funded, "open" research and business activities often cannot
be drawn. It may not be clear which hat the scientist and his
students and technicians are wearing at any given moment.
This has already led to divisive problems at universities everywhere. The extent and nature of business-related activity on
campus may not even be discernable, given the nature of the
work and funding.
Moreover, extensive networking exists that makes it difficult to obtain disinterested counsel from scientists. A professor may not have his own company, but perhaps his collaborators or his own graduate advisor holds stock and sits on the
board of some companies. His graduate students may have
taken positions at other universities and formed their own
companies there.
The issue of"power" is never far off. Within science and the
academy, who should have the power to say how genetic
engineering should be developed? Who should control the
dialogue and the agenda of discussion? It becomes harder for
genetic engineers to admit others into the discussion when it
seems that the discussion on campus could affect business
prospects and may not remain purely "academic."
Every book that I have seen in this area warns that biotechnology will present unusually severe challenges for universi ties. Yet, for whatever reasons, university policies are usually
to proceed full steam ahead with development programs and
to ignore opportunities to explore the broader implications of
biotechnology. Perhaps it generally is as one dean told me
plainly when I raised this issue a few years ago, "Don't assume
that there is any group of wise men that sits around to decide
what is right and how to do it. This is a very political place.
Money talks, and political clout."
Many university administrators encourage campus involvement with business. In part, this is because career ladders can

be influenced by the size of the budget an administrator
controls or has jurisdiction over. In part, this is also because
business and government ties are often important in campus
politics. There is also clearly some truth to the argument for
public consumption that more money means larger programs
and more activity. The implication that this necessarily means
higher quality scholarship or more "important" scholarship is
notoriously open to dispute.
Ecologists, too, as other scientists and scholars, are confined by their own training, disciplinary boundaries, and
grant-renewal agendas. They are focused on their own career
ladders and have their own interests.
Biotechnology raises exciting intellectual issues for scholars not only in biology but also in economics, sociology,
agriculture, philosophy of science, political science, international relations, and the humanities. But disciplinary isolation
and campus politics create inertia against taking up such
issues in more than a sporadic way. New external funding
could counter such inertia. Departments and administrators
are unlikely to give priority to hiring new faculty, giving merit
raises, space, time, etc., unless external funding seems secure.
There is presently no rush to fund studies and education in
these areas.
The National Academy of Sciences has often been criticized
for not being able, as a body, to maintain a sufficiently disinterested stance on public issues because many of its members
in physics, chemistry, engineering, and now molecular biology have ties to business and the military. For whatever reasons, it has largely pushed for rapid development and has not
volunteered an agenda for meeting the public concerns mentioned here.
Government
The priority in government is to develop biotechnology as
rapidly as possible. In part, this is because the economy has
been bad for some years and it is hoped that biotechnology
can offer some relief to local and national problems. Politicians see the overriding concern of voters to be economic
recovery. Other public concerns seem "philosophical" or
"idealistic" in this light.
Health and environmental concerns are seen as having
enough political currency to merit attention at some level.
Around these issues a small infrastructure has developed of
informed scientists on congressional staffs, and in agencies
such as the National Science Foundation, and especially the
Environmental Protection Agency (EPA). The EPA began its
preparations relatively early, in anticipation of the need to
evaluate proposals for introductions of GEOs into ,the
environment.
There is even a small amount of funding available for
individual, particular research grants that may be helpful here.
So far these funds have come from other programs and have
been criticized for this reason. There has not been funding for
scholars to study and consider broad issues, or for a broad
interdisciplinary education effort. Nor have funds been
appropriate to the scale of the issue.
A Catch-22 is part of the problem. Some congressional
leaders are urging the development of vehicles to meet
broader concerns. But they are wisely reluctant to appropriate
funds until they are certain that the money can be well used
and will not simply be absorbed by ever-present opportunists
for traditional uses under new labels. Scientists and scholars,
though, are reluctant to invest the time and effort to educate
themselves deeply on these complex issues unless they can
foresee secure funding.
The intellectual and political support of industry has been
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sought in developing a national agenda. But as mentioned,
the priority of industry is to develop rapidly and it has been
reluctant to agree that the study of broader social concerns is
its problem.
A second sort of infrastructure is developing around issues
related to agriculture and biotechnology. This too is modest in
size.
The few qualified people on the Washington scene work
long and hard and much of their energy is absorbed by topical
issues such as regulation. They seem to change agencies often
and this also absorbs much energy. Some leave government
payrolls to become lobbyists and consultants. It is not clear
how much time, energy, and freedom they have to contribute
to the elucidation and solutions of the concerns collected
above. In any event, biotechnology is here to stay and the
range and complexity of the present and potential issues
dwarf the available talent.
Recently, I have seen the emergence of some informed
people in state agencies, primarily in connection with regulatory issues. It is not clear if this is the start of a trend or in what
direction such a trend might lead.

Conclusions
Ideally, scientists, scholars, and qualified citizens would be
financially and politically free to interact and to study and
prepare to offer wise counsel on the interesting and profound
challenges that our new technological future is presenting to
society. They could contribute greatly to the development of a
sound policy and to the development of necessary institutional changes. They could help educate a generation to meet
the mushrooming challenges of the future. The system is not,
though, set up by itself to encourage and support such free
inquiry. Free inquiry is discouraged by
1) a polarized and emotional controversy with a confused
history and hardened perceptions on the part of some;
2) intrinsically complex interdisciplinary issues;
3) the disciplinary politics and financial incentive structures
of academics;
4) the direct financial interests of many scientists and of the
public organizations in which they have power;
5) the fear of raising issues that may slow development.
So where shall society get its wise counsel?Will it do to have
the individual thinker here and there who writes an occasional book, or who does his or her job well? The lesson of
history is that such individual efforts will merely spotlight the
folly that tends to unfold when serious issues are ignored on
an institutional level. We will need new and focused political
and economic support for programs to educate people who
can grasp the details of these issues, research them, work out
sound policies, and answer specific questions at an appropriate level of detail and understanding.

References
1. Regal, P.]. 1987. Safe and effective biotechnology: mobil-

izing scientific expertise. (In press) In: John Fowles III
(ed.) Application of Biotechnology: Enviromental and
Policy Issues. AAAS Symposium. Boulder, Colorado: Westview Press.
2. Jackson, D.A., and Stitch, S.P. (eds.) 1979. The Recombinant DNA Debate. Englewood Cliffs, NewJersey: PrenticeHall.
3. Krimsky, S. 1982. Genetic Alchemy: The Social History of
the Recombinant DNA Controversy. Cambridge, Massachusetts: MIT Press.

31

4. Watson,J.D. , and Tooze,J. 1981. The DNA Story: A Documentary Story of Gene Cloning. San Francisco: W.H.
Freeman and Company.
5. Regal, PJ. 1985. The ecology of evolution: implications of
the individualistic paradigm. In : H. Halvorson, D. Pramer,
M. Rogul (eds.), Engineered Organisms in the Environment, pp. 11-19. Washington, D.C.: American Society for
Microbiology.
6. Regal, P.]. 1986. Models of genetically engineered organisms and their ecological impact. In: H. Mooney and].
Drake (eds.), Ecology of Biological Invasions of North
America and Hawaii, pp. 111-129. NewYork: SpringerVerlag.
7. Regal, PJ. , 1986. Natural history in the era of genetic
engineering. Imprint3( 4): 1-3, 8. QFB Museum, University of Minnesota)
8. Wright, S., 1987. New designs for biological weapons.
Bull of the At. Sci. 43(1) : 43-46.
9. Murray, TJ. 1985. Ethical issues in genetic engineering.
Social Res. 52: 471-489.
10. Panem, S. 1984. The Interferon Crusade. Washington,
D.C.: The Brookings Institution.

11. Yanchinski, S. 1987. Boom and bust in the bio business.
New Scientist, jan. 22, 1987.

General References
1. jonas, H. 1985. Ethics and biogenetic art. Social Res. 52 :
491-504.
2. Kenney, M. 1986. Biotechnology: The University-Industrial
Complex. New Haven, Connecticut: Yale University Press.
3. Novick, R. , 1987. Bullish on DNA. (Review of Biotechnology: The University-Industrial Complex by M. Kenney)
New York Times Book Review. Feb. 15, 1987.
4. Price, DJ. de Solla. 1986 ( 1963). Little Science, Big Science
and Beyond. New York: Columbia University Press.
5. Regal , PJ. 1985. Review of The Gene Business: Who
Should Control Biotechnology?, by E. Yoxen. Bioscience 35
(9): 596-8.
6. Regal, PJ. 1985. Review of Recombinant DNA Research
find the Human Prospect by E.D. Hanson (ed.) Bioscience 35 (9): 596-8.
7. Yoxen, E. 1983. The Gen e Business: Who Should Control
Biotechnology? New York: Harper & Row.

A Broad Perspective on Biotechnology
and Environmental Regulation
GLENN L. RADDE

Glenn L. Radde is a Senior State Planner in the Office of Planning at the Department of Natural Resources.

I think that it is of the utmost importance to keep the
political and scientific sides of biotechnology well balanced
within the realm of public policy. There are at least two
discernible groupings of people regarding biotechnology.
There are those who sing its praises and those who ponder
how little we really know of basic life processes.
In the public policy arena, government is often caught in a
netherworld between promises and realities-where it is
often difficult to find truly honest, impartial advisors. While
the public expects the government to act on everyone's
behalf, interest groups representing the "public" get especially upset when they are slighted. For example, it is hard for
anyone to deny a company help that is willing to invest large
amounts of money in economically depressed areas. It is
equally hard for an elected official to ignore companies who
create more jobs than the typical margin of victory in local
elections.
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Very briefly, environmental regulation in the biotechnology
area stems from the efforts in the 1970s of various federal
agencies (e.g., National Institutes of Health (NIH) , National
Science Foundation (NSF) , Environmental Protection Agency
( EPA). In December, 1984, the White House Office of Science
and Technology published in the Federal Register a "Proposal
for a Coordinated Framework for Regulation of Biotechnology" to standardize and harmonize the federal agencies' regulatory posture (1 ).
Within this document, the EPA, Food and Drug Administration (FDA), and U.S. Department of Agriculture ( USDA) published statements of policy defining the areas of biotechnologywith which they would be most concerned. FDA was to be
concerned only if undesirable foreign materials are introduced into pharmaceutical or food preparations. USDA saw no
difference between recombinant DNA-derived plants and traditional crossbred variants. Finally, EPA considered its role to
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